Global Nuclear Medicine Radiopharmaceutic Market Size By Type (Tc99, I-123/131), By Application (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2023 to 2032

The Global Nuclear Medicine Radiopharmaceutical Market was valued at USD 7.9 billion in 2023 and is projected to reach USD 18.6 billion by 2031, growing at a CAGR of 11.3% during the forecast period from 2023 to 2031. The market is being propelled by the increasing prevalence of cancer and cardiovascular diseases, rising geriatric population, advancements in radiotracer development, and growing adoption of personalized medicine. Nuclear medicine radiopharmaceuticals are playing a crucial role in precise diagnostics and targeted therapies, making them an indispensable component of modern healthcare.

Drivers:

Rising Incidence of Chronic Diseases:

The surge in cancer and cardiovascular disease cases worldwide is significantly boosting demand for nuclear imaging and therapeutic solutions. Radiopharmaceuticals enable early detection, accurate diagnosis, and effective treatment monitoring, contributing to improved patient outcomes.

Technological Advancements:

Innovations in imaging techniques such as PET and SPECT, combined with newer radiotracers, are enhancing image resolution and targeting capabilities. This has broadened the clinical application scope of radiopharmaceuticals beyond oncology to include neurology and cardiology.

Supportive Regulatory Environment:

Increased support from regulatory bodies, including faster approval pathways for radiopharmaceuticals and isotopes, is accelerating market entry and adoption of novel compounds.

Restraints:

High Cost and Short Half-Life:

Radiopharmaceuticals often require expensive cyclotrons and radiochemistry infrastructure. Additionally, the short half-life of isotopes demands swift logistics and specialized handling, which can limit accessibility in under-resourced regions.

Limited Reimbursement Policies:

The absence of comprehensive reimbursement in several countries hampers the widespread use of nuclear medicine procedures, especially in developing economies.

Opportunity:

Expansion in Emerging Markets:

Rapid urbanization, increasing healthcare investments, and rising awareness about diagnostic precision are opening lucrative opportunities in emerging economies such as India, Brazil, and Southeast Asia.

Growth of Theranostics:

The evolving field of theranostics, which combines diagnostics and therapeutics in a single platform, is driving demand for targeted radiopharmaceuticals. This dual approach offers personalized treatment and better clinical outcomes, especially in oncology.

Market by System Type Insights:

Based on system type, the Positron Emission Tomography (PET) Radiopharmaceuticals segment held the largest share in 2023. This dominance is attributed to PET’s superior imaging capabilities and its pivotal role in early cancer detection. Furthermore, the Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals segment is witnessing robust growth due to its cost-effectiveness and expanding application in cardiology and neurology diagnostics.

Market by End-use Insights:

The Hospitals & Clinics segment emerged as the largest end-user in 2023, accounting for over 45% of market revenue. Hospitals remain the primary providers of nuclear medicine services due to their access to imaging equipment and trained radiologists. Meanwhile, diagnostic centers are expected to exhibit the fastest growth, driven by rising outsourcing trends and expanding access to affordable imaging solutions.

Market by Regional Insights:

North America led the global nuclear medicine radiopharmaceutical market in 2023, supported by a robust healthcare infrastructure, favorable reimbursement policies, and presence of key players. However, Asia-Pacific is poised to witness the fastest growth during the forecast period, propelled by increasing healthcare expenditure, improving diagnostic capabilities, and government initiatives promoting nuclear medicine adoption.

Competitive Scenario:

Key players in the global market include GE Healthcare, Siemens Healthineers, Cardinal Health, Lantheus Holdings, Curium Pharma, Jubilant Radiopharma, Advanced Accelerator Applications (Novartis), and Bracco Imaging. These companies are actively engaging in product innovations, acquisitions, and strategic partnerships to expand their radiopharmaceutical portfolios and strengthen global distribution networks.

Scope of Work – Global Nuclear Medicine Radiopharmaceutical Market

Key Market Developments:

2023: GE Healthcare launched a new digital PET/CT platform designed for oncology and cardiology applications, enhancing image resolution and workflow efficiency.

2024: Curium Pharma announced a strategic partnership with a leading Asian diagnostics group to expand radiopharmaceutical access in Southeast Asia.

2025: Novartis’ Advanced Accelerator Applications division gained FDA approval for a new theranostic radioligand therapy for prostate cancer.

FAQs:

1) What is the current market size of the Global Nuclear Medicine Radiopharmaceutical Market?

The market was valued at USD 7.9 billion in 2023.

2) What is the major growth driver of the Global Nuclear Medicine Radiopharmaceutical Market?

Rising prevalence of chronic diseases and advancements in radiotracer technologies are major growth drivers.

3) Which is the largest region during the forecast period in the Global Nuclear Medicine Radiopharmaceutical Market?

North America currently dominates, while Asia-Pacific is projected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Nuclear Medicine Radiopharmaceutical Market?

The PET Radiopharmaceuticals segment held the largest share in 2023.

5) Who are the key market players in the Global Nuclear Medicine Radiopharmaceutical Market?

Key players include GE Healthcare, Siemens Healthineers, Cardinal Health, Lantheus Holdings, and Curium Pharma.